Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001155 · ClinicalTrials.gov registry record · Phase 2
Treatment of Wegener's Granulomatosis With Cyclophosphamide
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00001155 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 200 participants.
The verdict
NCT00001155, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Interventions
- DRUG cyclophosphamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 1976-02 |
| Est. Completion | 2002-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001155
The ClinicalTrials.gov registry entry for NCT00001155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which cyclophosphamide is the first listed.
NCT00001155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001155 about?
NCT00001155 is a clinical study titled "Treatment of Wegener's Granulomatosis With Cyclophosphamide". The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigato...
What is the current status of trial NCT00001155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 1976-02. Estimated completion is 2002-02.
What interventions are being tested in trial NCT00001155?
The interventions under investigation include: cyclophosphamide (DRUG).
Who is sponsoring clinical trial NCT00001155?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.